A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma

Trial Profile

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With INCB024360 or Placebo in Subjects With Unresectable or Metastatic Melanoma

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 08 May 2017

At a glance

  • Drugs Epacadostat (Primary) ; Ipilimumab
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 03 May 2017 Status changed from active, no longer recruiting to discontinued as Further development of this compound with ipilimumab in the treatment of melanoma is no longer being pursued..
    • 28 Feb 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Apr 2017.
    • 23 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top